Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$375MCash on Hand
17.8mo Cash Runway
Follow FDMT by emailGet an email when FDMT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FDMT, unsubscribe in one click. Privacy
📣 What FDMT Says Is Next
at year-end · 4D-710: “4D-710 for Cystic Fibrosis: o AEROW Phase 1/2 clinical trial and program update expected at year-end Q3 2026 Financial Results Cash Position: Cash, cash equivalents and marketable securities were $375.0 million as of September 30, 2026, as compared to $514.0 million as of December 31, 2025.”
Company press release, Nov 12, 2026 · SEC filing
H2 2027 · “Enrollment completed in June 2026 and randomization completed (N=531) in August 2026; topline data expected in H2 2027 o PRISM Phase 1/2 Clinical Trial:”
Company press release, Nov 12, 2026 · SEC filing
Q2 2027 · “Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively”
Company press release, Nov 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 net loss of $78.1 million versus $56.9 million a year earlier, with R&D expenses of $69.8 million tied to Phase 3 wet AMD trials. Cash, equivalents and marketable securities were $375.0 million, expected to fund operations into the second half of 2028. Topline 4FRONT-1 data is expected in Q2 2027. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 28, 2026 ·
Clinical trial Enrolled first patients across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for DME (N=514 planned), and reported 2-year SPECTRA data: no ocular serious adverse events, mean BCVA gain of +10.8 letters at the Phase 3 dose (n=9), and 61% treatment burden reduction versus on-label aflibercept. Form 8-K · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 net loss of $72.9 million, up from $54.7 million, with R&D expenses of $68.3 million and cash of $430.6 million to fund operations into the second half of 2028. Secured a credit facility of up to $200 million from Hercules Capital with an initial $20 million draw. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 1/2 · Recruiting · 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration Registry primary completion date, not a results date
May 2027 · Phase 1 · Active Trial · Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia Registry primary completion date, not a results date
Jun 2027 · Phase 2 · Recruiting · 4D-710 in Adult Patients With Cystic Fibrosis Registry primary completion date, not a results date
Jun 2027 · Phase 3 · Active Trial · 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration Registry primary completion date, not a results date
Nov 2027 · Phase 3 · Recruiting · Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration Registry primary completion date, not a results date
Jan 2029 · Phase 3 · Recruiting · A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not FDMT's own candidates): Aflibercept.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
FDMT holds $375M in cash and short-term investments (as of Sep 30, 2026) and burns about $63.4M/quarter from operations,
an estimated runway of 17.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:57 · Elevated
Cash runway 18 months +18
ATM program on file since Jun 2024 +15
Shelf registration (S-3, May 2026) +10
Share count +50% in a year +14
Recent financing filings on SEC EDGAR:
May 7, 2026 · Shelf registration, up to $400M · S-3
Share count 49,778,127 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full FDMT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FDMT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.